Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Cost of RevenueGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Guided Therapeutics (GTHP) Preferred Shares Issued (2015 - 2021)

Guided Therapeutics recorded quarterly Preferred Shares Issued of $1.3 million in Q4 2021, up 200.0% quarter-over-quarter from -$1.3 million in Q3 2021.

Guided Therapeutics' Preferred Shares Issued history runs 2 years deep, the most recent figure standing at $1.3 million for Q4 2021.

  • In Q4 2021, Preferred Shares Issued changed N/A year-over-year to $1.3 million; the TTM figure through Sep 2022 stood at $1.3 million (up 948.8% YoY), while the FY2021 annual figure was $1.4 million, changed N/A from the prior year.
  • Preferred Shares Issued came in at $1.3 million for Q4 2021 at Guided Therapeutics, up from -$1.3 million in the prior quarter.
  • In the past five years, Preferred Shares Issued ranged from a high of $1.8 million in Q1 2021 to a low of -$1.3 million in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Guided Therapeutics - - 458,000.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 1.31 Mn
Dec 31, 2021 1.31 Mn
Sep 30, 2021 -1.31 Mn
Sep 30, 2021 -1.31 Mn
Jun 30, 2021 -382,000.00
Jun 30, 2021 -382,000.00
Mar 31, 2021 1.82 Mn
Mar 31, 2021 1.82 Mn
Dec 31, 2015 583,000.00
Dec 31, 2015 583,000.00
Sep 30, 2015 1.08 Mn
Sep 30, 2015 1.08 Mn
Jun 30, 2015 1.58 Mn
Jun 30, 2015 1.58 Mn
Mar 31, 2015 451,000.00
Mar 31, 2015 451,000.00